Back to all bills
Standard Summary
Comprehensive overview in 1-2 paragraphs
The PLASMA Act amends Medicare's manufacturer discount program to phase in discounts for plasma-derived products, which are biological products derived from human blood or plasma.
Key Points
- 1Establishes a phase-in schedule for plasma-derived products under Medicare Part D manufacturer discount program
- 2Sets specified discount percentages that decrease over time (99% in 2026 to 90% by 2030 for most beneficiaries)
- 3Provides different discount rates for beneficiaries who have vs. haven't met out-of-pocket thresholds
- 4Applies to plasma-derived products marketed as of August 16, 2022
- 5Excludes certain drugs dispensed to LIS beneficiaries and specified small manufacturers
- 6Applies to years 2026 and subsequent
Impact Areas
Medicare Part D beneficiariesManufacturers of plasma-derived productsPharmaceutical industryMedicare prescription drug program costs
Generated by kwaipilot/kat-coder-pro:free on Nov 19, 2025